Fulcrum Therapeutics Stock Performance
| FULC Stock | USD 10.87 0.53 5.13% |
On a scale of 0 to 100, Fulcrum Therapeutics holds a performance score of 6. The firm shows a Beta (market volatility) of -1.42, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Fulcrum Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Fulcrum Therapeutics is expected to outperform it. Please check Fulcrum Therapeutics' jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to make a quick decision on whether Fulcrum Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Fulcrum Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of rather conflicting essential indicators, Fulcrum Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 5.13 | Five Day Return 11.95 | Year To Date Return (0.46) | Ten Year Return (19.48) | All Time Return (19.48) |
1 | Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 12/05/2025 |
2 | Disposition of 3452 shares by Oltmans Curtis Gale of Fulcrum Therapeutics at 12.92 subject to Rule 16b-3 | 12/15/2025 |
3 | Wall Street Analysts Think Fulcrum Therapeutics Could Surge 58.47 percent Read This Before Placing a Bet | 12/30/2025 |
4 | Disposition of 15000 shares by Gould Robert J of Fulcrum Therapeutics at 11.8726 subject to Rule 16b-3 | 01/02/2026 |
5 | Fulcrum Therapeutics, Inc. Stock Analysis A Biotech With A 90 percent Upside Potential - DirectorsTalk Interviews | 01/08/2026 |
6 | Can Fulcrum Therapeutics Inc. disrupt its industry - Weekly Trading Summary Free Low Drawdown Momentum Trade Ideas - bollywoodhelpline.com | 01/14/2026 |
7 | Acquisition by Tourangeau Greg of 6500 shares of Fulcrum Therapeutics subject to Rule 16b-3 | 01/21/2026 |
8 | Acquisition by Sapir Alex of 650000 shares of Fulcrum Therapeutics at 10.72 subject to Rule 16b-3 | 02/02/2026 |
| Begin Period Cash Flow | 26.7 M | |
| Total Cashflows From Investing Activities | 32.2 M |
Fulcrum Therapeutics Relative Risk vs. Return Landscape
If you would invest 865.00 in Fulcrum Therapeutics on November 14, 2025 and sell it today you would earn a total of 222.00 from holding Fulcrum Therapeutics or generate 25.66% return on investment over 90 days. Fulcrum Therapeutics is currently generating 0.6379% in daily expected returns and assumes 7.7912% risk (volatility on return distribution) over the 90 days horizon. In different words, 70% of stocks are less volatile than Fulcrum, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Fulcrum Therapeutics Target Price Odds to finish over Current Price
The tendency of Fulcrum Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 10.87 | 90 days | 10.87 | about 44.55 |
Based on a normal probability distribution, the odds of Fulcrum Therapeutics to move above the current price in 90 days from now is about 44.55 (This Fulcrum Therapeutics probability density function shows the probability of Fulcrum Stock to fall within a particular range of prices over 90 days) .
Fulcrum Therapeutics Price Density |
| Price |
Predictive Modules for Fulcrum Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Fulcrum Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Fulcrum Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Fulcrum Therapeutics is not an exception. The market had few large corrections towards the Fulcrum Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Fulcrum Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Fulcrum Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.89 | |
β | Beta against Dow Jones | -1.42 | |
σ | Overall volatility | 1.46 | |
Ir | Information ratio | 0.09 |
Fulcrum Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Fulcrum Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Fulcrum Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Fulcrum Therapeutics is way too risky over 90 days horizon | |
| Fulcrum Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 80 M. Net Loss for the year was (9.72 M) with loss before overhead, payroll, taxes, and interest of (52.4 M). | |
| Fulcrum Therapeutics currently holds about 221.79 M in cash with (2.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.26. | |
| Over 81.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 |
Fulcrum Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Fulcrum Stock often depends not only on the future outlook of the current and potential Fulcrum Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Fulcrum Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 62 M | |
| Cash And Short Term Investments | 241 M |
Fulcrum Therapeutics Fundamentals Growth
Fulcrum Stock prices reflect investors' perceptions of the future prospects and financial health of Fulcrum Therapeutics, and Fulcrum Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fulcrum Stock performance.
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | 480.58 M | ||||
| Shares Outstanding | 65.97 M | ||||
| Price To Earning | (1.99) X | ||||
| Price To Book | 3.40 X | ||||
| Price To Sales | 5.12 X | ||||
| Revenue | 80 M | ||||
| Gross Profit | (52.4 M) | ||||
| EBITDA | (18.24 M) | ||||
| Net Income | (9.72 M) | ||||
| Cash And Equivalents | 221.79 M | ||||
| Cash Per Share | 4.26 X | ||||
| Total Debt | 8.63 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 15.49 X | ||||
| Book Value Per Share | 3.67 X | ||||
| Cash Flow From Operations | (2.22 M) | ||||
| Earnings Per Share | (1.14) X | ||||
| Market Capitalization | 682.13 M | ||||
| Total Asset | 260.72 M | ||||
| Retained Earnings | (519.4 M) | ||||
| Working Capital | 238.88 M | ||||
| Current Asset | 22.54 M | ||||
| Current Liabilities | 3.5 M | ||||
About Fulcrum Therapeutics Performance
By analyzing Fulcrum Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Fulcrum Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Fulcrum Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Fulcrum Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (2.85) | (2.71) | |
| Return On Tangible Assets | (0.03) | (0.04) | |
| Return On Capital Employed | (0.08) | (0.08) | |
| Return On Assets | (0.03) | (0.04) | |
| Return On Equity | (0.04) | (0.04) |
Things to note about Fulcrum Therapeutics performance evaluation
Checking the ongoing alerts about Fulcrum Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fulcrum Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fulcrum Therapeutics is way too risky over 90 days horizon | |
| Fulcrum Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 80 M. Net Loss for the year was (9.72 M) with loss before overhead, payroll, taxes, and interest of (52.4 M). | |
| Fulcrum Therapeutics currently holds about 221.79 M in cash with (2.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.26. | |
| Over 81.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 |
- Analyzing Fulcrum Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fulcrum Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Fulcrum Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fulcrum Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fulcrum Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fulcrum Therapeutics' stock. These opinions can provide insight into Fulcrum Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |